Maria Grazia Roncarolo believes her company could redefine treatments for conditions like multiple sclerosis (MS), Crohn's disease, and other autoimmune diseases. Closer to Cures Dr. Roncarolo, co-founder, president, and head of R&D at San Diego-based Tr1X Bio, said in a recent presentation that her company is modifying the patient’s own immune system to calm cells … Continue reading Tr1X Bio aims to Redefine Cell Therapy for Autoimmune Diseases
By Holly Alyssa MacCormick If you or someone you love is living with a chronic disease, you know that navigating uncertainty and getting answers can be one of the hardest parts of the journey. That’s why Aditi Desai’s work matters. As the community outreach manager for the California Institute for Regenerative Medicine (CIRM), Desai focuses on … Continue reading Connecting with and engaging Californians for public health
When Alameda-based biotech company and CIRM awardee Scribe Therapeutics raised over $155 million from a recent IPO, it became the latest in a series of companies developing CIRM-supported therapies that have gone public or netted significant follow-on funding and investment. That’s good news for Californians whose tax dollars support the companies’ work. While biotech IPOs … Continue reading Another proof point from CIRM-supported research